XXXX and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.

@entity1 @entity986 @entity957 @entity281 @entity1082
BACKGROUND: @entity1082 ) @entity281 indicates favorable prognosis in @entity957 (SCC). The purpose of this study was for us to assess the impact of HPV in @entity1 treated with sequential therapy versus concomitant chemoradiotherapy (CRT). METHODS: @entity1 with stage III and IVA and B oropharyngeal SCC were reviewed spanning 10 years. RESULTS: Among 500 cases, 291 (58%) received CRT versus 209 (42%) sequential therapy. HPV status was known in 279 of @entity1 (56%) and positive in 77% (determined by polymerase chain reaction [PCR; 91%], @entity986 immunohistochemical [IHC], or both). Median follow-up was 2.8 years. Overall survival (OS) did not differ for sequential therapy versus CRT overall (hazard ratio [HR]   =   0.90; p   =   .66; 3-year OS   =   86% and 87%) or within HPV-positive @entity1 (HR   =   0.89; p   =   .81; 3-year OS   =   91% and 91%) or within HPV-negative @entity1 (HR   =   0.55; p = .32; 3-year OS   =   85% and 75%). CONCLUSION: Survival for all @entity1 was high and notable for HPV-negative @entity1 treated with sequential therapy. Further studies in this @entity1 population are warranted.    2015 Wiley Periodicals, Inc. Head Neck 38: E1618-E1624, 2016.
